# PRAISE-IR Versus CIBMTR Controls

> **NCT07717164** · — · NOT_YET_RECRUITING · sponsor: **Miltenyi Biomedicine GmbH** · enrollment: 51 (estimated)

## Conditions studied

- ALL (Acute B-Lymphoblastic Leukemia)
- AML (Acute Myeloid Leukemia)
- MDS (Myelodysplastic Syndrome)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07717164
- **Lead sponsor:** Miltenyi Biomedicine GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2026-09-20
- **Final completion:** 2026-09-30
- **Target enrollment:** 51 (ESTIMATED)
- **Last updated:** 2026-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07717164

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07717164, "PRAISE-IR Versus CIBMTR Controls". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07717164. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*